The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > November 26, 2025
Daily News
November 26, 2025
- Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
- Taisho Touts Low Next-Day Carryover for New Insomnia Drug Vorzzz
November 26, 2025
- US FDA Probes Takeda’s Adzynma after Reported Pediatric Death
November 26, 2025
- Celecoxib Faces Unified Pushback Against Rx-to-OTC Switch
November 26, 2025
- Labor Group Presses Lawmakers to Reflect Rising Costs in Drug Prices
November 26, 2025
- Alfresa/Mycenax-Led Biosimilar JV to Be Named Alfenax Biologics
November 26, 2025
- Chugai Targets Japan Filing in 2026 for Ranibizumab Eye Implant
November 26, 2025
- Allergan Japan Files TrenibotE for Glabellar Lines Treatment
November 26, 2025
- Taiho Begins Rolling US NDA Submission for Zipalertinib
November 26, 2025
- Padcev/Keytruda Wins US Nod for Perioperative Bladder Cancer Use
November 26, 2025
- Otsuka Files Novel ADHD Drug Centanafadine in US
November 26, 2025
- Novartis Eyes Broader Radioligand Therapy Footprint in Japan as Pluvicto Debuts
November 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…